跳至主要内容

Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association

 Recently, the China Laboratory Primate Breeding and Development Association Industry Academic Exchange Conference and 30th Anniversary Celebration were held as scheduled at the Dragon Lake Princess Hotel in Huadu, Guangzhou.  As a member, Shanghai Medicilon Inc. was invited to attend the conference and was awarded the "Industry Outstanding Member Unit Management Award".

Nonhuman primate research is an indispensable part of preclinical research and plays a link between basic research and clinical trial.  As a one-stop biopharmaceutical preclinical R&D service platform in China, Medicilon established a "non-human primate professional technical service platform" as early as 2008.  After nearly 16 years of experience and technology accumulation, the non-human primate professional technical service platform has established mature models in the fields of ophthalmic diseases, inflammatory and autoimmune diseases, endocrine, metabolic diseases and more.  Medicilon can provide pharmacodynamics, pharmacokinetics and safety evaluation tests in compliance with international and China GLP specifications, international AAALAC requirements, FDA standards and ICH requirements, providing strong support for promoting clinical development.

Industry Outstanding Member Unit Management Award.webp

It is worth mentioning that Medicilon's "Professional Technical Service Platform for Non-Human Primates" has been selected into the Shanghai International Services Trade Demonstration Project.  At present, Medicilon has complete animal models such as mice, rats, rabbits, pigs, dogs, and monkeys, which can meet clients' different types of new drug research and development needs.  Among them, the non-human primate experimental facility is the largest laboratory in Shanghai with the largest number of monkeys.

Medicilon respects the life of experimental animals, pays attention to the welfare ethics of experimental animals, and actively implements the "3Rs" principles of use of experimental animals and the "Five Basic Welfare", providing different toys, sports facilities, nutritious fruits, play light music and cartoons for different species of experimental animals to ensure that the animals are in a comfortable, healthy, happy and natural living state.

In the future, Medicilon will maintain and protect the welfare of experimental animals, cherish every experimental opportunity, provide high-quality and efficient scientific research services for global new drug research and development, and empower the innovative development of life sciences.

PS: We would like to express our highest respect to all experimental animals that devote themselves to life sciences!

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文